Combination therapies for cancer: challenges and opportunities
Authors:
Open Access
- 4 May 2023
- journal article
- research article
- Published by Springer Nature in BMC Medicine
- Vol. 21 (1) , 1-3
Abstract
Background: Gastrointestinal cancers represent a major challenge to public health. Pancreatic cancer is the most lethal cancer among all gastrointestinal cancers. Most patients cannot meet the criteria of resection at diagnosis, indicating these patients will have dismal prognosis. Main text: Neoadjuvant chemotherapy helps some patients regain the opportunity of radical resection. An optimal regimen of chemotherapy is one that maximizes the anti-tumor efficacy while maintaining a relatively manageable safety profile. The development of surgical procedures further improves the outcomes of these patients. Conclusions: Combination therapies in a multidisciplinary manner that involves modified chemotherapy regimen, radical resection, and intestine auto-transplantation may provide the currently best possible care to patients with locally advanced pancreatic cancer.Keywords
This publication has 10 references indexed in Scilit:
- Radical Resection Combined With Intestinal Autotransplantation for Locally Advanced Pancreatic Cancer After Neoadjuvant TherapyAnnals of Surgery, 2023
- Gut flora disequilibrium promotes the initiation of liver cancer by modulating tryptophan metabolism and up-regulating SREBP2Proceedings of the National Academy of Sciences, 2022
- Living Donor Intestinal TransplantationAnnals of Surgery, 2022
- Randomized phase III study of sintilimab in combination with modified folfrinox versus folfrinox alone in patients with metastatic and recurrent pancreatic cancer in China: The CISPD3 trial.Journal of Clinical Oncology, 2022
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesCA: A Cancer Journal for Clinicians, 2021
- Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 studyThe Lancet Gastroenterology & Hepatology, 2020
- The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancerPancreatology, 2020
- Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese PopulationThe Oncologist, 2018
- Modified-FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese populationCancer Letters, 2017
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011